Literature DB >> 19699962

The first open-heart repairs using extracorporeal circulation by cross-circulation: a 53-year follow-up.

James H Moller1, Sara J Shumway, Vincent L Gott.   

Abstract

Between March 26, 1954 and July 19, 1955, C. Walton Lillehei and colleagues operated upon 45 infants and children with previously uncorrectable cardiac anomalies using cross-circulation with a human donor. Late follow-up was obtained in all of the 28 patients discharged after the operation. All of the 20 currently living patients were personally interviewed with regard to their cardiac status. Eight early survivors have died. Three died after repair of a residual cardiac anomaly. Another died 4 months postoperatively from heart failure. The other 4 died 13 to 47 years later: 2 of unknown causes, 1 of pneumonia, and 1 was an accident. Eleven late cardiac operations were performed. Seven were done to correct a residual anomaly. More than 40 years later, 2 patients underwent procedures to correct tricuspid regurgitation. One had a mitral valve procedure, and another underwent coronary artery bypass grafting. Of the current 20 survivors, none is limited from cardiac causes. Considering that these 45 patients represent "the dawn of open-heart surgery," the long-term results are quite remarkable.

Entities:  

Mesh:

Year:  2009        PMID: 19699962     DOI: 10.1016/j.athoracsur.2009.05.077

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Sixty Years After Tetralogy of Fallot Correction.

Authors:  Chetan Shenoy; James H Moller
Journal:  Ann Thorac Surg       Date:  2018-07-02       Impact factor: 4.330

2.  Normothermic Ex Vivo Heart Perfusion: Effects of Live Animal Blood and Plasma Cross Circulation.

Authors:  Joseph T Church; Fares Alghanem; Kristopher B Deatrick; John M Trahanas; Joseph P Phillips; Min Hee Song; Elena M Perkins; Robert H Bartlett; Alvaro Rojas-Pena; Martin L Bocks; Gabe E Owens
Journal:  ASAIO J       Date:  2017 Nov/Dec       Impact factor: 2.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.